Clinical features and prognostic factors in patients with multiple myeloma
Objective To explore the clinical features and prognostic factors of patients with multiple myeloma(MM).Method The clinical data characteristics of 63 patients with multiple myeloma in our hospital were retrospectively analyzed,and then the relevant influencing factors of myeloma patients were analyzed.Results The single-factor results affecting the prognosis of OS by Log-Rank analysis were as follows:the factors that were meaningful to the prognosis of patients with multiple myeloma were:age,ISS stage,whether PR was reached after induction,three-drug combination regimen,fluorescence in situ hybridization FISH high-risk ge-netic abnormalities,lactate dehydrogenase(LDH)(P<0.05);The results of COX multivariate analysis showed that fluorescence in situ hybridization FISH had high-risk genetic abnormalities,lactate dehydrogenase(LDH)≥240 U/L and multiple myeloma OS prog-nosis(P<0.05).The single-factor results affecting the prognosis of PFS by Log-Rank analysis were as follows:the factors that were meaningful with the prognosis of multiple myeloma patients were:age,hemoglobin(Hb),blood calcium,ISS stage,whether PR was reached after induction,fluorescence in situ hybridization FISH high-risk genetic abnormalities,lactate dehydrogenase(LDH)(P<0.05);The results of COX multivariate analysis showed that there were high-risk genetic abnormalities in fluorescence in situ hybrid FISH,lactate dehydrogenase(LDH)≥240 U/L,and PR not reached after induction and MMPFS were statistically significant(P<0.05).The ORR rate of the three-drug combination group containing bortezomib was higher than that in the two-drug combination group(P=0.000).Conclusion Patients with high-risk genetics and high lactate dehydrogenase multiple myeloma have a poor progno-sis.For patients with multiple myeloma,three-drug chemotherapy is more beneficial than two-drug combination.
Multiple MyelomaLactate dehydrogenaseFluorescence in situ hybridization FISH high-risk geneticsClinical fea-turesPrognosis
万方数据
维普
